Automated point-of-care PCR for hemorrhagic fever diagnosis

描述（由申请人提供）：该项目的总体目标是开发一种经过验证的全自动、便携式、即时核酸检测系统，用于快速诊断由NIAID a -c类生物防御病原体引起的出血热综合征。病毒性出血热的实验室诊断目前由于需要专门实验室和技术专长而变得复杂。因此，对疑似病毒性出血热的明确诊断出现延误，这对流行地区的临床护理和发达国家的生物防御准备工作都是一个问题。IQuum公司拥有一项专有的“试管实验室”（Liat）技术，该技术代表了一种有前途的方法，可以为哨点或现场实验室提供出血热病毒的诊断能力。Liat系统由专有的分析管系统和分析设备组成，为快速、自动化的标本处理和核酸检测提供了一个封闭的系统。该项目提出了马萨诸塞大学的病毒学家、IQuum公司的工程师和美洲热带地区的合作者之间的合作研究和开发计划，以推进Liat系统的开发，特别是用于快速和敏感地检测病毒性出血热药物。该项目的具体目标是：1。推进Liat分析仪的工程设计，提高可靠性，易于制造，增强多重分析能力，从而产生适合部署在哨点和现场实验室的分析仪。2. 定义和优化由NIAID A-C类病毒引起的病毒性出血热综合征的诊断和预后评估的检测方法。我们的重点将是开发血清和全血中登革热病毒RNA的检测和定量方法，并将扩展到开发登革热预后标记物和其他出血热病原体的检测方法。3. 开发适合于向FDA提交IDE申请的临床前和临床数据组合，以批准Liat登革热病毒感染鉴别诊断测定。该项目将推进一种新型封闭式全自动检测平台的开发，该平台适用于前线（护理点）检测引起出血热的病毒。检测验证将首先侧重于一种商业上可行的检测登革热病毒的检测方法，并将扩展到检测其他病毒。

DESCRIPTION (provided by applicant): The overall objective of this project is to develop a validated fully automated, portable, point-of-care nucleic acid detection system for rapid diagnosis of hemorrhagic fever syndromes caused by NIAID category A-C biodefense pathogens. The laboratory diagnosis of viral hemorrhagic fever is currently complicated by the need for specialized laboratories and technical expertise. The resulting delays in definitive diagnosis of suspected viral hemorrhagic fever is a problem for clinical care in endemic regions and for biodefense readiness in developed countries. IQuum, Inc. has a proprietary "laboratory-in-a-tube" (Liat(tm)) technology that represents a promising approach to provide diagnostic capability for hemorrhagic fever viruses to sentinel or field laboratories. The Liat system, consisting of a proprietary assay tube system and analyzer device, provides a closed system for rapid, automated specimen handling and nucleic acid detection. This project proposes a cooperative research and development program between virologists at the University of Massachusetts, engineers at IQuum, Inc, and collaborators in tropical areas in the Americas to advance the development of the Liat system specifically for the rapid and sensitive detection of viral hemorrhagic fever agents. The Specific Aims of the project are: 1. To advance the engineering of the Liat Analyzer for improved reliability, ease of manufacture, and enhanced multiplex assay capability assays, thus yielding analyzers suitable for deployment in sentinel and field laboratories. 2. To define and optimize assays for diagnosis and prognostic evaluation of viral hemorrhagic fever syndromes caused by NIAID category A-C viruses. Our focus will be on development of assays for detection and quantitation of dengue viral RNA in serum and whole blood, and will extend to development of assays for prognostic markers in dengue and for detection of other hemorrhagic fever pathogens. 3. To develop a portfolio of pre-clinical and clinical data suitable for an IDE filing with the FDA for approval of the Liat differential diagnostic assay for dengue virus infection. This project will advance the development of a novel closed, fully automated assay platform suitable for front-line (point of care) detection of viruses that cause hemorrhagic fevers. Assay validation will focus initially on a commercially viable assay for detecting dengue virus and be extended to detection of other viruses.